EZ-2053 5mg/kg ( DrugBank: - )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 85 | Idiopathic interstitial pneumonia | 1 |
| 299 | Cystic fibrosis | 1 |
85. Idiopathic interstitial pneumonia
Clinical trials : 627 / Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00105183 (ClinicalTrials.gov) | January 2005 | 8/3/2005 | EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection | A Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of an Anti-human-T-lymphocyte Immune Globulin (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary Pulmonary Allograft(s) | Chronic Obstructive Pulmonary;Idiopathic Pulmonary Fibrosis;Cystic Fibrosis;Bronchiectasis;Pulmonary Vascular Disease | Biological: Placebo;Biological: EZ-2053;Biological: EZ-2053 5mg/kg | Neovii Biotech | NULL | Completed | 18 Years | N/A | All | 223 | Phase 3 | United States;Australia;Austria;Canada |
299. Cystic fibrosis
Clinical trials : 1,695 / Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00105183 (ClinicalTrials.gov) | January 2005 | 8/3/2005 | EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection | A Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of an Anti-human-T-lymphocyte Immune Globulin (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary Pulmonary Allograft(s) | Chronic Obstructive Pulmonary;Idiopathic Pulmonary Fibrosis;Cystic Fibrosis;Bronchiectasis;Pulmonary Vascular Disease | Biological: Placebo;Biological: EZ-2053;Biological: EZ-2053 5mg/kg | Neovii Biotech | NULL | Completed | 18 Years | N/A | All | 223 | Phase 3 | United States;Australia;Austria;Canada |